End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
12.71 CNY | +1.68% | +3.00% | -33.53% |
Apr. 23 | Menovo Pharmaceutical Unit Gets Approval to Register Vildagliptin Tablets | MT |
Mar. 06 | Menovo Pharma's Unit Gets Nod to Market Clopidogrel Hydrogen Sulfate Tablets | MT |
Sales 2023 * | 1.5B 206M | Sales 2024 * | 1.75B 241M | Capitalization | 2.71B 374M |
---|---|---|---|---|---|
Net income 2023 * | 120M 16.56M | Net income 2024 * | 229M 31.6M | EV / Sales 2023 * | 1.81 x |
Net cash position 2023 * | - 0 | Net cash position 2024 * | - 0 | EV / Sales 2024 * | 1.55 x |
P/E ratio 2023 * |
22.7
x | P/E ratio 2024 * |
11.9
x | Employees | 2,297 |
Yield 2023 * |
-
| Yield 2024 * |
-
| Free-Float | 68.38% |
1 day | +1.68% | ||
1 week | +3.00% | ||
Current month | -9.34% | ||
1 month | -11.18% | ||
3 months | -19.46% | ||
6 months | -33.14% | ||
Current year | -33.53% |
Managers | Title | Age | Since |
---|---|---|---|
Cheng Zhi Yao
CEO | Chief Executive Officer | 49 | 04-02-18 |
Gao Feng Ying
DFI | Director of Finance/CFO | 53 | 19-10-11 |
Xiao Qing Zhang
IRC | Investor Relations Contact | - | - |
Members of the board | Title | Age | Since |
---|---|---|---|
Cheng Zhi Yao
CEO | Chief Executive Officer | 49 | 04-02-18 |
Zhi Yan Fan
PRN | Corporate Officer/Principal | 41 | - |
Qian Cao
BRD | Director/Board Member | 42 | 18-06-19 |
Date | Price | Change | Volume |
---|---|---|---|
24-04-25 | 12.71 | +1.68% | 2,242,291 |
24-04-24 | 12.5 | +0.81% | 1,554,804 |
24-04-23 | 12.4 | +0.16% | 2,157,040 |
24-04-22 | 12.38 | +1.81% | 2,351,171 |
24-04-19 | 12.16 | -1.46% | 2,363,270 |
End-of-day quote Shanghai S.E., April 24, 2024
More quotesEPS Revisions
Annual profits - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
-33.53% | 374M | |
+24.87% | 556B | |
-6.33% | 354B | |
+19.90% | 331B | |
+7.95% | 296B | |
+13.34% | 233B | |
+5.57% | 201B | |
-10.14% | 193B | |
-12.26% | 143B | |
-6.47% | 144B |
- Stock Market
- Equities
- 603538 Stock